Advertisement
Advertisement
Trending on CancerNetwork
1
112 First-Line (1L) Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (mTNBC) for Whom Immunotherapy Was Not an Option: Primary Results From the Randomized, Phase 3 TROPION-Breast02 Trial
2
Shifting Hematologic and Solid Tumor Units to Progressive Care Models
3
How Does the Removal of Heparin Impact Safety in Oncology Care?
4
111 The Aurora Kinase A Inhibitor Alisertib Alone or in Combination With Endocrine Therapy for Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Metastatic Breast Cancer (MBC)
5